Show simple item record

dc.contributor.authorAsh, S
dc.date.accessioned2022-05-18T13:20:02Z
dc.date.available2024-05-31T00:00:00Z
dc.date.issued2022-05-31
dc.identifier.citation2022en
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5138
dc.description.abstractAdvances in T-cell engineering have facilitated the generation of CAR T-cells that successfully deplete malignant cells of haematological cancers. However, attempts to target solid tumours with CAR T-cells have been hindered by the unfavourable environments surrounding the malignant cells in this setting. An alternative approach that circumvents the arduous journey to reach tumour cells is to target cells of the tumour microenvironment, especially those proximal to the vasculature. Endosialin is a transmembrane glycoprotein upregulated on tumour-associated pericytes and fibroblasts which has previously been shown by our laboratory to have a role in promoting tumour cell intravasation and metastatic dissemination. The aim of this PhD was to evaluate endosialin-targeting CAR T-cells, known as Endo3 CAR T-cells, in the context of solid tumours. In vitro characterisation of Endo3 CAR T-cells demonstrated endosialin-specific activation and cytotoxicity against both mouse and human cells. Endo3 CAR T-cells were evaluated in vivo in the context of three synegeneic models of cancer: 4T1, AT-3 and LLC. Modest effects on primary tumour growth were observed in 4T1 and LLC tumour-bearing mice, however a significant reduction in spontaneous lung metastasis was observed in these models. Conversely, in AT-3 tumour-bearing mice, Endo3 CAR T-cell therapy resulted in a significant reduction of primary tumour growth but did not limit metastatic lung disease. Endo3 CAR T-cell therapy was associated with toxicity in BALB/c 4T1 tumour-bearing mice that was not alleviated by anti-IL-6R treatment or delivering multiple low T-cell doses. Interrogation of the strain-specific Endo3 CAR T-cell products revealed differences in the CD4+:CD8+ T-cell ratio and distinct efficacies in an immunodeficient setting. This thesis proposes that Endo3 CAR T-cell therapy is a potential candidate for targeted therapy of solid tumours. Further studies are required to gain better understanding of Endo3 CAR T-cell dosing and tolerability in the context of different endogenous immune systemsen_US
dc.languageeng
dc.language.isoeng
dc.publisherInstitute of Cancer Research (University Of London)
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectTheses, Doctoralen_US
dc.subjectCancer Biologyen_US
dc.subjectCell Therapyen_US
dc.titleTargeting the tumour microenvironment with endosialin-directed CAR T-cellsen
dc.typeThesis or Dissertation
dcterms.accessRightsPublic
dcterms.licensehttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.versionAO
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2022-05-31
rioxxterms.typeThesis
pubs.notes24 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Cell Biology
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.embargo.terms24 monthsen_US
pubs.embargo.date2024-05-31T00:00:00Z
icr.researchteamMolecular Cell Biology
dc.contributor.icrauthorAsh, Sarahen_US
uketdterms.institutionInstitute of Cancer Research
uketdterms.qualificationlevelDoctoral
uketdterms.qualificationnamePh.D
dc.type.qualificationlevelDoctoral
dc.type.qualificationnamePh.D


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record